 Biogen Inc NASDAQ: BIIB and Eisai Co Ltd OTC: ESALY launched a real-world, Phase 4 study to evaluate the long-term effects of the Aduhelm aducanumab-avwa 100 mgmL solution for injection this time, with a focus on recruiting more patients from minority groups. The companies are looking for 6,000 Alzheimers patients with mild cognitive impairment or mild dementia to participate in an observational study dubbed ICARE AD-US. 